SCHEMBL6681187

SCHEMBL6681187

CN1CC(C(=O)O)=Cc2c1n(C)c(=O)n(Cc1ccc(F)c(F)c1)c2=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.35
PTGS2 P35354 2/20 0.35
DPP4 P27487 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
PKM P14618 1/20 0.34
RAB9A P51151 1/20 0.34
ALDH1A1 P00352 4/20 0.34
TSHR P16473 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
GRIN1 Q05586 3/20 0.34
GRIN2B Q13224 3/20 0.34
POLB P06746 1/20 0.33
P2RX3 P56373 1/20 0.33
S1PR3 Q99500 1/20 0.33
NTRK1 P04629 1/20 0.33
MMP13 P45452 1/20 0.32
SLC22A8 Q8TCC7 1/20 0.32
BRD4 O60885 1/20 0.32
SIGMAR1 Q99720 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6681995 0.85 SMN1; SMN2 (0.48) SMN1; SMN2PKMRAB9AALDH1A1TSHR
SCHEMBL6705127 0.83 PTGS1 (0.38) PTGS1PTGS2DPP4SMN1; SMN2PKM
SCHEMBL6683778 0.81 PARP1 (0.39) PTGS1PTGS2SMN1; SMN2ALDH1A1TSHR
SCHEMBL6663839 0.80 ALDH1A1 (0.36) PTGS1PTGS2DPP4SMN1; SMN2PKM
SCHEMBL6692406 0.80 ALDH1A1 (0.36) PTGS1PTGS2DPP4ALDH1A1TSHR
SCHEMBL6679104 0.80 PTGS1 (0.36) PTGS1PTGS2DPP4ALDH1A1TSHR
SCHEMBL7115999 0.71 TRPA1 (0.42) SMN1; SMN2PKMALDH1A1TSHRPOLB
SCHEMBL6466057 0.70 MMP13 (0.57) PTGS1PTGS2PTGDR2MMP13SLC22A8
SCHEMBL6698891 0.70 PTGS1 (0.41) PTGS1PTGS2PTGDR2GRIN1GRIN2B
SCHEMBL6683636 0.69 PARP1 (0.34) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 PTGS1 494/4885PTGS2 984/4885DPP4 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.